Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - dolutegravir sodium - film coated tablet - 10

Kenya - English - Pharmacy and Poisons Board

dolutegravir (as sodium), lamivudine, tenofovir… - tablet - 50 mg/ 300 mg/ 300 mg - lamivudine, tenofovir disoproxil and dolutegravir

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

emcure pharmaceutical limited., india - dolutegravir sodium, lamivudine , tenofovovir disoproxil fumarate - tablets - dolutegravir 50mg/lamivudinr 300mg/tenofovir 300 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

camber laboratories sdn. bhd. - dolutegravir sodium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mylan healthcare sdn. bhd. - dolutegravir sodium -

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ampol australia petroleum pty ltd - liquid paraffin (heavy) - emulsifiable concentrate - liquid paraffin (heavy) ungrouped active 847.0 g/l - insecticide

European Union - English - myHealthbox

merck sharp & dohme limited - lamivudine, raltegravir potassium - film-coated tablets - 150 mg of lamivudine and 300 mg of raltegravir - hiv infections - antivirals for systemic use - indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the insti (integrase strand transfer inhibitor) and nrti (nucleoside reverse transcriptase inhibitor) classes

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 702 mg (equivalent: abacavir, qty 600 mg); lamivudine, quantity: 300 mg; dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; povidone; magnesium stearate; purified water; mannitol; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - trelavue is indicated for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age who are antiretroviral treatment-na?ve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents (dolutegravir, abacavir or lamivudine) in trelavue.

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg - isentress1 is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adult patients. this indication is based on analyses of plasma hiv-1 rna levels up through 48 weeks in three double-blind controlled studies of isentress. two of these studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, nrti, pi) treatment-experienced adults and one was conducted in treatment-naïve adults. the use of other active agents with isentress is associated with a greater likelihood of treatment response [see clinical studies (14)] . the safety and efficacy of isentress have not been established in pediatric patients. registered trademark of merck & co., inc. copyright © 2007, 2009 merck & co., inc. all rights reserved none pregnancy category c isentress should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there are no adequate and well-controlled studies in pregnant women. in addi

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - raltegravir potassium (unii: 43y000u234) (raltegravir - unii:22vkv8053u) - raltegravir 400 mg - isentress® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection. this indication is based on analyses of plasma hiv-1 rna levels through 96 weeks in three double-blind controlled studies of isentress. two of these studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, nrti, pi) treatment-experienced adults and one was conducted in treatment-naïve adults. the use of other active agents with isentress is associated with a greater likelihood of treatment response [see clinical studies (14)] . isentress is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in children and adolescents 2 years of age and older and weighing at least 10 kg [see use in specific populations (8.4)] . this indication is based on the evaluation of safety, tolerability, pharmacokinetic parameters and efficacy of isentress through at least 24-weeks in a multi-center, open-label, noncomparative study